BHVN — Biohaven Ltd. stock price, charts and financials

QT52Biohaven Ltd.

Biohaven Ltd. (NYSE: BHVN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
13.62
-0.27-1.94%
OverviewShort InterestFilings
BHVNQT52Biohaven Ltd.·NYSE
13.62-1.94%
News
Down 1.9% — Xenon Stock Craters on Drug Trial Setback. Its Failure Could Be This Rival’s Gain. (Yahoo).
Medium confidence
TA
Loading chart...
Signal & projected range
QT Score downgradeHistorical pattern — not a prediction
Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
NUVB-3.62%$5.85RXRX+8.19%$3.83CMPS+1.27%$15.19VCEL-0.03%$40.02KOD-0.43%$32.71ADMA+1.79%$9.11GPCR-0.28%$35.00URGN-1.59%$43.25
Snapshot
Index-P/E-EPS (ttm)-15.26Insider Own32.21%Shs Outstand150.56MPerf Week7.16%
Market Cap2.06BForward P/E-EPS next Y-2.50Insider Trans0.00%Shs Float123.75MPerf Month-3.68%
Enterprise Value2.08BPEG-EPS next Q-0.61Inst Own-Short Float15.35%Perf Quarter0.37%
Income-889.00MP/S10.79EPS this Y82.14%Inst Trans-Short Ratio6.27Perf Half Y52.01%
Sales190.00MP/B170.89EPS next Y8.21%ROA-158.29%Short Interest19.00MPerf YTD20.64%
Book/sh0.08P/C7.65EPS next 5Y-ROE-1328.94%52W High18.57 -26.66%Perf Year-7.35%
Cash/sh1.78P/FCF-EPS past 3/5Y-ROIC-181.44%52W Low7.48 82.09%Perf 3Y-28.39%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility7.60% 8.59%Perf 5Y-
Dividend TTM-EV/Sales10.95EPS Y/Y TTM-64.44%Oper. Margin0.00%ATR (14)1.14Perf 10Y-
Dividend Ex-Date-Quick Ratio4.73Sales Y/Y TTM-Profit Margin0.00%RSI (14)46.91Recom2.40
Dividend Gr. 3/5Y-Current Ratio4.73EPS Q/Q53.09%SMA20-5.54%Beta1.25Target Price20.00
Payout0.00%Debt/Eq5.37Sales Q/Q-SMA50-5.42%Rel Volume2.14Prev Close13.89
Employees274LT Debt/Eq5.37EarningsNov 09SMA20014.63%Avg Volume3.00MPrice13.62
IPO DateSep 23, 2022Option/ShortYes / YesEPS/Sales Surpr.-19.58% -Net Debt/EBITDA-0.10Volume6,418,424Change-1.94%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-08-26DowngradeRBC CapitalOutperform → Sector Perform$22 → $19
Aug-28-26ReiteratedCanaccord GenuityBuy$21
Aug-26-26ReiteratedRaymond James$30
Aug-12-26ReiteratedMorgan StanleyOverweight$18 → $19
Jun-29-26ReiteratedNeedham$11
Jun-29-26DowngradeB of A SecuritiesNeutral → Underperform
May-13-26ReiteratedMorgan StanleyOverweight$26 → $18
Mar-04-26ReiteratedHC Wainwright & Co.Neutral$11 → $10
Mar-03-26ReiteratedLeerink PartnersOutperform$15
Feb-05-26InitiatedGoldman SachsBuy$23
Latest News· Times ET
Sep-18-26
Sep-18-2608:48AM
Xenon Stock Craters on Drug Trial Setback. Its Failure Could Be This Rival’s Gain.Yahoo
Sep-11-26
Sep-11-2602:28PM
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)prnewswire.com
07:17AM
Biohaven’s epilepsy drug hit with FDA clinical holdYahoo
Sep-10-26
Sep-10-2601:17PM
Biohaven: The Hold Isn't The Problem (Rating Downgrade)SeekingAlpha
10:14AM
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.barrons.com
06:43AM
FDA Pauses New Enrollment for Biohaven Epilepsy Drug Programbenzinga.com
03:37AM
US FDA pauses new enrollment in Biohaven's epilepsy drug trialsreuters.com
Sep-03-26
Sep-03-2607:59AM
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy BetYahoo
Aug-28-26
Aug-28-2603:32AM
Why Biohaven Stock Was Rocking the Market This WeekYahoo
12:12AM
BlackRock Inc. Invests $196.57 Million in Biohaven Ltd. $BHVNdefenseworld.net
Aug-27-26
Aug-27-2610:21AM
Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And Moreseekingalpha.com
07:30AM
Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levelsseekingalpha.com
06:46AM
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Programzacks.com
Aug-26-26
Aug-26-2609:41AM
Why Is Biohaven Stock Soaring Wednesday?Benzinga
Aug-25-26
Aug-25-2611:00PM
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsygurufocus.com
Company

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
19000—————
Cost of Goods Sold Incl. D&A4440—————
Gross Profit145-40—————
Selling, General and Administrative Excl. Other57210689—————
Research and Development253635796—————
Other Operating Expense
6200—————
Operating Income-742-745-885—————
Interest Expense
-700—————
Unusual Expense
————————
Non-Operating Income (Expense)231839—————
Net Income Before Taxes-503-737-846—————
Income Taxes1711—————
Consolidated Net Income-889-739-846—————
Net Income From Continuing Operations-521-739-846—————
Net Income-889-739-846—————
EPS (Recurring)-15.26-6.86-9.28—————
EPS (Basic, Before Extraordinaries)-15.26-6.86-9.28—————
EPS (Diluted)-15.26-6.86-9.28—————
EBITDA-481-727-838—————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio
4.66———————
Gross Margin
76.32———————
Operating Margin
-390.53———————
Net Margin
-467.89———————
Shares Outstanding6510891—————
Market Capitalization8851,2193,399—————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$19.66$16.30$12.95$9.60$6.24● Close Price0.00M8.29M16.57M24.86M33.14MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
CHILDS JOHN WDirectorMar 04 '25Buy30.4561,1001,860,3542,323,971Mar 09
Gentile KimberlySVP, Clinical OperationsJan 05 '26Option Exercise0.003,7500101,513Jan 07
Buten MatthewChief Financial OfficerJan 05 '26Option Exercise0.004,2500198,246Jan 07
Coric VladChief Executive OfficerJan 05 '26Option Exercise0.0014,25001,811,398Jan 07
Car BruceChief Scientific OfficerJan 05 '26Option Exercise0.004,750010,096Jan 07
Clark George C.VP, Chief Accounting OfficerJan 05 '26Option Exercise0.002,500068,095Jan 07
Clark George C.VP, Chief Accounting OfficerNov 17 '25Buy8.5217,000144,77020,000Nov 18
Bailey GregoryDirectorNov 13 '25Buy7.50400,0003,000,0002,020,071Nov 17
CHILDS JOHN WDirectorNov 13 '25Buy7.503,333,33324,999,9985,653,904Nov 17
Coric VladChief Executive OfficerNov 13 '25Buy7.50666,6664,999,9961,195,275Nov 17
CHILDS JOHN WDirectorApr 22 '24Buy41.00268,29110,999,9314,096,512Mar 05
Car BruceChief Scientific OfficerJan 05 '25Option Exercise0.004,75007,133Jan 07
Gentile KimberlySVP, Clinical OperationsJan 05 '25Option Exercise0.003,750099,719Jan 07
Clark George C.VP, Chief Accounting OfficerJan 05 '25Option Exercise0.002,500066,168Jan 07
Buten MatthewChief Financial OfficerJan 05 '25Option Exercise0.004,2500196,013Jan 07
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.